Skip to main content

Advertisement

SpringerLink
Log in

18F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 12 April 2014

Abstract

Objectives

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) plays an important role in many oncological settings. In this study, we assessed the utility of 18F-FDG-PET for predicting the histological classification, stage and survival of thymic epithelial tumors.

Methods

We retrospectively analyzed 37 patients with thymic epithelial tumors who underwent PET before surgical resection and investigated the relationship between the maximum of standardized uptake value (SUVmax) of each tumor and the WHO classification, recurrence-free survival, and tumor-related gene expressions.

Results

The study included 15 males and 22 females, ranging in age from 22 to 81 years (mean 64 years). The tumor histology of 31 tumors was thymoma and that of the remaining tumors was thymic carcinoma. The Masaoka tumor stage was as follows: stage I in 18, II in 9, III in 5 and IV in 5 patients. The patients were divided into three groups according to a simplified histologic classification: low-risk thymoma (types A, AB and B1, n = 21), high-risk thymoma (types B2 and B3, n = 10) and thymic carcinoma (n = 6). The SUVmax of low-risk group (SUVmax ≤4.27) was significantly lower than that of high-risk group (p = 0.0114) and that of thymic carcinomas (SUVmax >4.27) was also significantly higher than that of thymomas (p < 0.0001). The group of high SUVmax (SUVmax >4.27) had significantly inferior recurrence-free survival to that of less value (SUVmax ≤4.27) (p = 0.0009). The SUVmax were not correlated with tumor-related gene expressions.

Conclusion

The SUVmax of 18F-FDG-PET reflects WHO classification of thymic epithelial tumors. High SUVmax predicts lower recurrence-free survival of the tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol. 2001;25:103–10.

    Article  PubMed  CAS  Google Scholar 

  2. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624–32.

    Article  PubMed  Google Scholar 

  3. Fang W, Chen W, Chen G, et al. Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. Ann Thorac Surg. 2005;80:2002–7.

    Article  PubMed  Google Scholar 

  4. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using 18F-FDG PET-CT. Ann Nucl Med. 2009;23:569–77.

    Article  PubMed  Google Scholar 

  5. Benveniste MF, Moran CA, Mawlawi O, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;40:1595–601.

    Google Scholar 

  6. Sung Y, Lee K, Kim B, et al. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628–34.

    PubMed  Google Scholar 

  7. Müller-Hermelink HK, Möller P, Engel P, et al. Tumours of the thymus. In: Travis WD, Bramblla E, Müller-Hermelink HK, et al. editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart, World Health Organization classification of tumours. 7th ed. Lyon: IARC Press; 2004. p. 148–151.

  8. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–7.

    PubMed  CAS  Google Scholar 

  9. Inoue A, Tomiyama N, Tatsumi M, et al. 18F-FDG PET for the evaluation of thymic epithelial tumors: correlation with the World Health Organization classification in addition to dual-time-point imaging. Eur Nucl Med Mol Imaging. 2009;36:1219–25.

    Article  Google Scholar 

  10. Eguchi T, Yoshida K, Hamanaka K, et al. Utility of 18F-fluorodeoxyglucose positron emission tomography for distinguishing between the histological types of early stage thymic epithelial tumours. Eur J Cardiovasc Surg. 2012;41:1059–62.

    Article  Google Scholar 

  11. Fukumoto K, Taniguchi T, Ishikawa Y, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiovasc Surg. 2012;42:e152–6.

    Article  Google Scholar 

  12. Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, Ono A, Tsuya A, Nakamura Y, Naito T, Takahashi T, Endo M, Yamamoto N. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med. 2011;25:247–53.

    Article  PubMed  Google Scholar 

  13. Toba H, Kondo K, Sadohara Y, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1a, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiovasc Surg. 2013;44:e105–12.

    Article  Google Scholar 

  14. Nose A, Mori Y, Uchiyama-Tanaka Y, et al. Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens Res. 2003;26:67–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Thoracic Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, 321-0293, Japan

    Norio Seki, Yoko Karube, Takeshi Oyaizu, Hiromi Ishihama & Masayuki Chida

  2. Positron Emission Tomography Center, Dokkyo Medical University Hospital, 880 Kitakobayashi, Mibu, Tochigi, 321-0293, Japan

    Setsu Sakamoto

Authors
  1. Norio Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Setsu Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoko Karube
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Oyaizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromi Ishihama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayuki Chida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Chida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seki, N., Sakamoto, S., Karube, Y. et al. 18F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival. Ann Nucl Med 28, 257–262 (2014). https://doi.org/10.1007/s12149-014-0804-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-014-0804-2

Keywords

Search

Navigation